Tandem Diabetes Care (TNDM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.31
- Estimate
- -$0.32
- Surprise
- +2.8%
- Revenue (period 2026-06-30)
- $254.6M
- Score today
- 5.8/10
Revenue source: xbrl.
How the report landed
Tandem Diabetes Care (TNDM) reported a narrower loss than forecast — adjusted EPS of -$0.31 against the -$0.32 estimate (a 2.8% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates TNDM Sell at 5.8/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +2.8% surprise compares with a +33.2% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Supplier: Unomedical A/S
- Quality below floor (3.1 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $16.12
- Price target
- $24.99
- Stop
- $14.99
- Upside to target
- +55.0%
- Reward-to-risk
- 5.1:1
Model outputs from TrendMatrix’s engine as of 2026-10-15 — shown for context, not personalized investment advice.
TNDM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.11B
- P/E (fwd)
- 100.7
- 52-week range
- $12.26–$29.65
- Off 52-week high
- 45.6%
- RSI (14)
- 55
- Volume vs avg
- 1.48×
- Score today
- 5.8/10